Centene (NYSE: CNC) — 2026 Q2 Earnings Preview

Timing note: July 28, 2026 is today, not tomorrow. Centene is scheduled to release results at approximately 6:00 a.m. ET, followed by its earnings call at 8:30 a.m. ET. This preview is based on information available before the report. (investors.centene.com)

Executive view

This report is less about whether Centene beats a depressed quarterly EPS estimate and more about whether management can validate the three assumptions behind the stock’s sharp recovery:

1. Marketplace risk adjustment will compensate Centene for the higher acuity of its Silver-tier members.
2. Medicaid margins are recovering as rate increases and cost-management initiatives catch up with medical trend.
3. Medicare Advantage and Part D are progressing toward structurally better profitability in 2027.

Centene entered Q2 with considerable momentum. First-quarter adjusted EPS was $3.37, approximately $0.50 above management’s expectations, and full-year adjusted EPS guidance was raised to greater than $3.40. Medicaid and Medicare both outperformed, while Marketplace earnings were in line despite elevated utilization among Silver members. (investors.centene.com)

The challenge is that the stock now reflects a meaningful portion of that recovery. At roughly $64 before the report, CNC is about 47% above its April 27 pre-Q1 close. A routine beat may therefore be insufficient: investors will want better visibility into Marketplace risk adjustment and 2027 earnings.

Headline expectations

Consensus varies somewhat by provider, but the broad range is:

Metric	Approximate expectation
Q2 adjusted EPS	$0.90–$1.10
Q2 total revenue	$47.6 billion
FY2026 adjusted EPS	$3.45–$3.50
FY2027 adjusted EPS	$4.40–$4.50

One current estimate set has Q2 EPS at $1.08 and revenue at $47.64 billion; other services put EPS closer to $0.89. (marketbeat.com)

At approximately $64, the stock trades around 18.5x 2026 consensus EPS and 14x 2027 consensus. That is not demanding if margins normalize beyond 2027, but it is no longer a distressed valuation.

The five issues that should drive the reaction

1. Marketplace risk adjustment is the central swing factor

This is the most important item in the report.

Centene ended Q1 with approximately 3.58 million Marketplace members, down sharply from 5.63 million a year earlier following the expiration of enhanced premium subsidies and Centene’s pricing and product actions. Commercial HBR was 75.3%, slightly worse than expected, primarily because of elevated utilization among higher-acuity Silver-tier members before anticipated risk-adjustment offsets. (investors.centene.com)

On the Q1 call, management said:

• Early market data supported the conclusion that Centene retained a disproportionately acute Silver population.
• Centene expected a slight net risk-adjustment receivable rather than its previous payable assumption.
• Guidance embedded an approximately 3% Marketplace pretax margin, below the original roughly 4% target.
• The forecast did not include the full potential benefit suggested by early data.
• The June Wakely industry data would be the key checkpoint.

Accordingly, investors should focus on:

• Whether June data corroborated the higher-acuity thesis.
• The size and accounting treatment of the expected risk-adjustment receivable.
• Whether the approximately 3% Marketplace margin assumption moves back toward 4%.
• Whether 2026 Marketplace guidance is raised, maintained or cut.
• What the latest information implies for 2027 pricing.

The peer read-through is mixed. Molina recently reported unfavorable Marketplace acuity and reduced its Marketplace outlook, even as Medicaid and Medicare improved. That does not directly predict Centene’s results, but it underscores how company-specific enrollment mix and risk adjustment can be. (investors.molinahealthcare.com)

Positive outcome: Management validates a meaningful receivable and raises the Marketplace margin outlook.

Negative outcome: Risk-score development fails to offset observed Silver-tier claims, forcing a higher Commercial HBR or lower full-year margin.

2. Medicaid must show fundamental—not weather-driven—improvement

Medicaid was the strongest part of Q1. Its HBR improved 50 basis points year over year to 93.1%, reflecting rate increases, cost-management initiatives and moderate flu. Centene’s Q1 Medicaid revenue rose 6% to $23.6 billion despite lower membership. (investors.centene.com)

Management entered Q2 assuming:

• A roughly 4.5% composite Medicaid rate yield.
• Net medical trend in the mid-4% range.
• Continued membership attrition.
• Higher Q2 and Q3 HBRs than Q1 because of normal quarterly seasonality.

That final point is important: a sequentially higher Medicaid HBR would not automatically represent deterioration. The better test is whether the Q2 result is consistent with or better than the company’s internal plan.

Key questions include:

• Are behavioral health, home health and high-cost drug trends stabilizing?
• Are autism/ABA utilization and billing controls producing durable savings?
• How much of the improvement comes from rates versus utilization management, network changes and payment integrity?
• Is management still confident that full-year Medicaid HBR can beat its prior approximately 93.7% expectation?
• Are states adequately incorporating post-redetermination acuity into rate updates?

Molina’s Q2 commentary that Medicaid rate/cost pressure had stabilized is a modestly constructive industry signal. (investors.molinahealthcare.com)

Separately, Centene’s Illinois Medicaid reprocurement removes an important contract risk. Meridian was selected for a new four-year contract beginning January 1, 2027; it served more than 596,000 Illinois Medicaid members as of May. (investors.centene.com)

3. Medicare and Part D need to prove that Q1 was not an unusually favorable quarter

The Medicare segment produced an 84.9% HBR in Q1, better than expected in both Medicare Advantage and Part D. Part D enrollment reached approximately 8.78 million, up from 7.87 million a year earlier. (investors.centene.com)

Q2 HBR should rise sequentially because Part D medical costs are seasonally back-end weighted. The relevant comparison is therefore against management’s expected slope, not against Q1’s unusually low ratio.

Investors should listen for:

• Specialty-pharmacy trend, particularly among non-low-income Part D members.
• Whether Q1’s favorable pharmacy utilization persisted.
• Confirmation that Medicare Advantage can reach breakeven in 2027.
• The economics of Centene’s 2027 MA and Part D bids.
• Progress in shifting MA enrollment toward dual-eligible and Medicaid-aligned members.
• Any change in expected Part D risk-sharing receivables.

A better-than-planned Medicare HBR would provide valuable protection if Marketplace risk adjustment remains uncertain.

4. Full-year guidance matters more than the quarterly beat

Centene earned $3.37 of adjusted EPS in Q1, yet its full-year guidance floor was only greater than $3.40. That unusual relationship reflects management’s expected earnings cadence:

• Q1: seasonally strongest.
• Q2: lower, but profitable.
• Q3: approximately breakeven.
• Q4: loss-making due to benefit seasonality and open-enrollment spending.

Thus, investors should not annualize first-half earnings. However, if Centene reports approximately $1 of Q2 EPS, it will have generated well over $4 of first-half adjusted EPS against a guidance floor of $3.40.

A guidance raise would therefore appear reasonable unless management sees material Marketplace, reserve or second-half cost risk. The quality of the raise will matter:

• A raise driven by Marketplace risk-adjustment confidence would be most constructive.
• A raise driven only by investment income, tax or SG&A would be less meaningful.
• Maintaining the $3.40 floor after another strong quarter could be interpreted as either prudence or evidence of significant second-half pressure.

The most useful disclosure would be an updated range—or at least a substantially higher floor—along with refreshed segment margin assumptions.

5. The market is already looking through 2026 to normalized earnings

With the stock near $64 and 2027 consensus EPS around $4.50, CNC trades at approximately 14x forward earnings. Investors are implicitly assuming further recovery beyond the current depressed margins.

Management therefore needs to connect Q2 performance to:

• Progressive Medicaid margin recovery in 2027.
• Marketplace profitability after 2026’s enrollment and subsidy disruption.
• Medicare Advantage breakeven.
• Sustainable Part D earnings.
• Lower interest expense and continued balance-sheet repair.

Centene repaid $1 billion of senior notes during Q1, reducing debt-to-capital to 43.2% from 46.5% at year-end. Further deleveraging would improve financial flexibility, although operating performance remains the more important catalyst. (investors.centene.com)

What would constitute a good report?

Bull case

• Adjusted EPS comfortably above $1.10.
• Marketplace data confirms a material risk-adjustment receivable.
• Marketplace margin moves toward or above the original 4% objective.
• Medicaid HBR is better than the company’s seasonal plan.
• Medicare and Part D remain ahead of expectations.
• Full-year adjusted EPS guidance rises meaningfully above current consensus.
• Management provides a credible path to stronger 2027 margins.

Base case

• EPS around $0.90–$1.10.
• Marketplace risk adjustment is directionally supportive but still uncertain.
• Medicaid and Medicare perform roughly to plan.
• Guidance is raised only modestly or management reiterates a conservative floor.
• Stock reaction is muted because the recovery is already partly priced in.

Bear case

• Marketplace claims remain elevated without sufficient risk-adjustment offsets.
• Commercial HBR or margin guidance deteriorates.
• Medicaid medical trend reaccelerates or rates fall behind acuity.
• Q1 Medicare favorability reverses sharply.
• Guidance is maintained or reduced despite strong reported first-half EPS.
• Management becomes less confident in 2027 MA breakeven or broader margin recovery.

Questions investors should want answered

1. What did the June Wakely data show, and how much Marketplace risk-adjustment benefit is now included in guidance?
2. What is the updated expected 2026 Marketplace pretax margin?
3. How did Q2 Medicaid HBR compare with the company’s internal seasonal forecast?
4. Is the 4.5% Medicaid rate yield still sufficient to cover net trend?
5. Which Medicaid cost categories are improving, and which remain elevated?
6. How much of Medicare’s Q1 outperformance continued into Q2?
7. Does Centene still expect MA breakeven in 2027?
8. What full-year earnings cushion remains after expected Q3 and Q4 seasonality?
9. How are work requirements and other Medicaid eligibility changes being incorporated into state rates and Centene’s 2027 planning?
10. When might stronger cash generation translate into additional debt reduction or share repurchases?

Bottom line

The cleanest investment thesis is that Centene’s 2025 problems represented a margin trough and that Medicaid, Marketplace and Medicare are now recovering together. Q1 supported that thesis, but Q2 must validate it with more complete claims and risk-adjustment data.

Marketplace is the decisive variable. If Centene confirms that risk adjustment offsets elevated Silver-tier claims while Medicaid and Medicare remain on track, the report can support further earnings revisions and a stronger 2027 outlook. If the Marketplace offset disappoints, the stock’s substantial post-Q1 rerating leaves less room for error—even if headline Q2 EPS beats consensus.